Reported full year 2025 financial results and provided a corporate update. Anticipate completing enrollment for the IFx-2.0 Phase 3 study in front-line Merkel Cell Carcinoma (MCC) in mid-2027. Initiated a randomized Phase 3 Accelerated Approval Trial for IFx-2.0 in first-line advanced or metastatic MCC as adjunctive therapy to Keytruda (pembrolizumab) under a Special Protocol Assessment (SPA) with the FDA. Initiated a Phase 1b/2a Study of IFx-2.0 as an adjunctive therapy to Keytruda in first-line metastatic MCC of Unknown Primary Origin (MCCUP). Closed the acquisition of Kineta for $10.5 million, gaining rights to TBS-2025, a novel VISTA inhibiting antibody. Raised gross proceeds of $21.2 million through registered direct offerings and private placements. Presented new data at ASH demonstrating the Delta Opioid Receptor (DOR) as a new target to overcome acquired resistance to immune checkpoint inhibitors. Cash and cash equivalents were $3.6 million at December 31, 2025, with an additional $7.5 million received in Q1 2026 from a 2025 registered direct offering. Research and development expenses increased to $20.5 million in 2025 from $13.3 million in 2024. General and administrative expenses increased to $7.6 million in 2025 from $3.9 million in 2024. Net cash outflows from operating activities increased to ($27.7) million in 2025 from ($14.7) million in 2024.